Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

cysteine/krabbamein

Krækjan er vistuð á klemmuspjaldið
Bls 1 frá 157 niðurstöður

Use of truncated cysteine IL28 and IL29 Mutants to treat cancers and autoimmune disorders

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION Cytokines generally stimulate proliferation or differentiation of cells of the hematopoietic lineage or participate in the immune and inflammatory response mechanisms of the body. Examples of cytokines which affect hematopoiesis are erythropoietin (EPO), which stimulates
This invention relates to N-acetyl-cysteine having the formula ##STR1## and has as its object the use of this compound to block cardiac damage resulting from the use of anthracyclines, notably adriamycin, in cancer therapy. The anthracyclines have the general formula ##STR2## and their essential
BACKGROUND OF THE INVENTION The present invention relates to novel receptors in the TNF family. A novel receptor has been identified, referred to herein as TRAIN (TNF Receptor in the BRAIN). The TNF family consists of pairs of ligands and their specific receptors referred to as TNF family ligands

6-substituted amino-4-oxa-1-azabicyclo [3,2,0] heptan-7-one derivatives as cysteine protease inhibitors

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION Cysteine proteases, such as cathepsins B, L, S, and O.sub.2, have been implicated in a number of diseases, including cancer metastasis and invasion (Clin. Exp. Metastasis 1992, 10, 145-155; Cancer Metastasis Rev. 1990, 9, 333-352), arthritis (Int. J. Biochem. 1993, 25,

Anti-transplanted tumor remedy

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
It is a purpose of this invention to create a cytostatic composition for treatment of transplanted tumors in animals by structurally combining antimetabolics (the hydrazide of cystine and of cysteine, respectively) with an alkylating group. In connection with the invention, U.S. Pat. No. 3,897,494,

Compounds for, and methods of, treating cancer and inhibiting invasion and metastases

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION The invention generally relates to the treatment of cancer, and, more specifically, to compounds that inhibit the ability of cancer cells to invade tissues and cause metastases. Such compounds and methods can be used alone, or together with other anticancer therapies

Inhibition of cancer procoagulant

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION This invention relates to selective peptidyl inhibitors of cancer procoagulant (CP), a protein elaborated by malignant, but not normal, animal and human cells, and to the use of these selective peptidyl inhibitors in cancer therapy and in CP removal from blood. BACKGROUND OF
BACKGROUND OF THE INVENTION 1. Technical Field The present invention relates to methods of producing form-specific antibodies for transforming growth factor (TGF)-.beta. subfamily compositions. More specifically, the present invention relates to methods of diagnosing cancer patients by measuring

Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
FIELD OF THE INVENTION The invention relates generally to the field of medicine, and relates specifically to methods and compositions for inhibiting tumor growth and angiogenesis in a tissue or detecting angiogenesis and tumor growth using compounds based on a specified sequence found within

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 28, 2014, is named IMM343US1_SL.txt and is 56,360 bytes in size. BACKGROUND OF THE

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 28, 2014, is named IMM343US1_SL.txt and is 56,360 bytes in size. BACKGROUND OF THE

Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 14, 2015, is named IMM316US4_SL.txt, and is 31,769 bytes in size. FIELD OF THE INVENTION The present

Tethering cysteine residues using cyclic disulfides

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION Many therapeutic molecules form covalent bonds with cysteine residues on their protein targets. The mechanisms of the majority of these molecules were either elucidated long after development or are not fully understood. Recent successful drug discovery efforts, however,

Peptides having a high cysteine content

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
TECHNICAL FIELD The present invention relates to peptides with a high cysteine content, to nucleic acid sequences encoding said peptides, to vectors comprising said sequences, as well as to pharmaceutical compositions containing said peptides and their use as pharmaceutics. STATE OF THE ART A

3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators

Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND OF THE INVENTION Cysteine proteinases containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as: muscular dystrophy (Am. J. Pathol. 1986,
Skráðu þig á
facebook síðu okkar

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

  • Virkar á 55 tungumálum
  • Jurtalækningar studdir af vísindum
  • Jurtaviðurkenning eftir ímynd
  • Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
  • Lestu vísindarit sem tengjast leit þinni
  • Leitaðu að lækningajurtum eftir áhrifum þeirra
  • Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum

Google Play badgeApp Store badge